Home » Athersys, Angiotech Announce Authorization of Stem Cell Clinical Trial
Athersys, Angiotech Announce Authorization of Stem Cell Clinical Trial
Co-developers Athersys Inc. and Angiotech Pharmaceuticals Inc. say they have received authorization from the U.S. Food and Drug Administration to begin clinical trials of a stem cell-based treatment for heart attacks.
The Canadian Press
The Canadian Press
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May